CLINICAL RESEARCH: HEART RHYTHM DISORDER
Trends in Anticoagulation for Atrial Fibrillation in the U.S.An Analysis of the National Ambulatory Medical Care Survey Database
Shane B. Rowan, MD*,
Desiree N. Bailey, BS ,
Caroline E. Bublitz, MS and
Robert J. Anderson, MD*,*
* Department of Medicine, University of Colorado at Denver and Health Sciences Center, Denver, Colorado
Department of Family Medicine, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado.
Manuscript received October 2, 2006;
revised manuscript received November 20, 2006,
accepted November 27, 2006.
* Reprint requests and correspondence: Dr. Robert J. Anderson, University of Colorado, Internal Medicine, 4200 East 9th Avenue, B178, Denver, Colorado 80262. (Email: robert.anderson{at}uchsc.edu).
Objectives: The purpose of this study was to track trends in the use of anticoagulation for atrial fibrillation (AF) over the past decade and identify predictors of use.
Background: Atrial fibrillation is common and associated with significant morbidity. Previous studies suggest underuse of anticoagulant therapy in patients with AF.
Methods: The National Ambulatory Medical Care Survey database was queried for all patient visits with a diagnosis of AF between 1994 and 2003. Other diagnoses, other medications, and demographic, visit, geographic, and provider characteristics were compared with the prescription of anticoagulation in predefined age and risk groups.
Results: The prevalence of the diagnosis of AF and anticoagulation for AF has increased over the last decade. Increased age and use of rate control agents is associated with the use of anticoagulation. There is a trend toward less anticoagulation when a rhythm control agent is used instead of a rate control agent. Anticoagulation might be overused in a group of low-risk patients.
Conclusions: From 1995 through 2002, an increase has occurred in anticoagulation for AF, especially in those at highest risk for thromboembolic phenomena. A substantial number of patients at risk for thromboembolic events are not anticoagulated, and further studies are needed to determine how many of these patients are candidates for anticoagulation. Anticoagulation use has increased in nontargeted, low-risk groups in whom antiplatelet agents are appropriate. Use of a rhythm control agent might be associated with less use of anticoagulation.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | NAMCS = National Ambulatory Medical Care Survey | | NCHS = National Center for Health Statistics |
|
This article has been cited by other articles:
|
|
|
|
 
C. Leclercq, L. Padeletti, R. Cihak, P. Ritter, G. Milasinovic, D. Gras, V. Paul, I.C. Van Gelder, C. Stellbrink, G. Rieger, et al.
Incidence of paroxysmal atrial tachycardias in patients treated with cardiac resynchronization therapy and continuously monitored by device diagnostics
Europace,
October 28, 2009;
(2009)
eup318v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Du, T. Ninomiya, B. de Galan, E. Abadir, J. Chalmers, A. Pillai, M. Woodward, M. Cooper, S. Harrap, P. Hamet, et al.
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study
Eur. Heart J.,
May 1, 2009;
30(9):
1128 - 1135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Nieuwlaat and S. J Connolly
Stroke prevention in atrial fibrillation: better use of anticoagulation and new agents will lead to improved outcomes
Heart,
January 15, 2009;
95(2):
95 - 97.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Claassen, N. Kazemi, A. Y. Zubkov, E. F. M. Wijdicks, and A. A. Rabinstein
Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage
Arch Neurol,
October 1, 2008;
65(10):
1313 - 1318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
